InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
1
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Pontifax Management 4 G.P. (2015) Ltd.. Officer active across 3 companies, notably Eloxx Pharmaceuticals, Inc.. In total, 4 reports have been logged. Breakdown: 1 buy · 1 sell. Total volume traded: €36.3m. Activity tracked since 13 May 2021. The latest transaction was disclosed on 15 October 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Pontifax Management 4 G.P. (2015) Ltd.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
2,284,612 shares@ US$17.75100.0% of flowCommon Stock, $0.0001 par value per shareSEC:0000921895-25-002765:0
411,681 sharesCommon StockSEC:0001726334-25-000003:0
3,539 shares100.0% of flowCommon StockSEC:0001209191-22-059053:0
1,280,624 shares@ US$1.35100.0% of flowCommon StockSEC:0001104659-21-067336:0
Canonical exit: 11 Aug 2021 (T+90)
4 of 4 declarations
About Pontifax Management 4 G.P. (2015) Ltd.
Pontifax Management 4 G.P. (2015) Ltd. is a declarant linked to Keros Therapeutics, Inc., LB PHARMACEUTICALS INC, and Eloxx Pharmaceuticals, Inc. It has 4 filings in total, and across the recent sample of 4 filings, the reported amounts are EUR 1431482 of purchases and EUR 34819452 of sales, with the first filing on 2021-05-17 and the last on 2025-10-17. The modal transaction nature is Cession.
